Medycyna Paliatywna

Udział medycyny paliatywnej w leczeniu choroby Parkinsona – pomijany aspekt kompleksowej opieki medycznej

Katarzyna Anna Mórdas-Żylińska 1
,
Monika Rudzinska 1
,
Tomasz Dzierżanowski 1, 2
,
Artur Frątczak 3

  1. Klinika Medycyny Paliatywnej, Warszawski Uniwersytet Medyczny, Warszawa, Polska


  2. Caritas Diecezji Warszawsko-Praskiej, Warszawa, Polska


  3. Klinika Medycyny Paliatywnej, Warszawski Uniwersytet Medyczny, Warszawa, Polska


Medycyna Paliatywna 2026; 18(2)

DOI: https://doi.org/10.5114/pm.2026.162163
Data publikacji online: 2026/06/05
Plik artykułu
Udział medycyny.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Ha TY, Kim JB, Kim Y, Park SM, Chang KA. GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson’s disease animal models. Pharmacol Res 2024; 209: 107432.
  2. Gierczyński J, Kułakowska A, Rejdak K. Neurologia w Polsce. Stan obecny i perspektywy rozwoju, 2024. Polskie Towarzystwo Neurologiczne 2024.
  3. Poewe W. The natural history of Parkinson’s disease. J Neurol 2006; 253: VII2-6.
  4. Kluger BM, Dolhun R, Sumrall M, Hall K, Okun MS. Palliative care and Parkinson’s disease: time to move beyond cancer. Mov Disord 2021; 36: 1325-1329.
  5. Buddhala C, Loftin SK, Kuley BM, Cairns NJ, Campbell MC, Perlmutter JS, Kotzbauer PT. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann Clin Transl Neurol 2015; 2: 949-959.
  6. Senderovich H, Jimenez Lopez B. Integration of palliative care in Parkinson’s disease management. Curr Med Res Opin 2021; 37: 1745-1759.
  7. Titova N, Chaudhuri KR. Palliative care and nonmotor symptoms in Parkinson’s disease and Parkinsonism. Int Rev Neurobiol Academic Press Inc. 2017; 134: 1239-1255.
  8. Kluger BM, Miyasaki J, Katz M, Galifianakis N, Hall K, Panti- lat S, Khan R i wsp. Comparison of integrated outpatient palliative care with standard care in patients with Parkinson disease and related disorders: a randomized clinical trial. JAMA Neurol 2020; 77: 51-560.
  9. Oliver D, Veronese S. Specialist palliative care for Parkinson’s disease. Ann Cardiothorac Surg 2020; 9: S52-S62.
  10. Neurological disorders: public health challenges. World Health Organization 2006.
  11. Minister Zdrowia. Rozporządzenie Ministra Zdrowia z dnia 29 października 2013 r. w sprawie świadczeń gwarantowanych z zakresu opieki paliatywnej i hospicyjnej. 2022:t.j. Dz. U. z 2022 r. poz. 262.
  12. Lum HD, Kluger BM. Palliative care for Parkinson disease. Clin Geriatr Med 2020; 36: 149-157.
  13. Miyasaki JM, Long J, Mancini D, Moro E, Fox SH, Lang AE i wsp. Palliative care for advanced Parkinson disease: an interdisciplinary clinic and new scale, the ESAS-PD. Parkinsonism Relat Disord 2012; 18: S6-9.
  14. Parkinson’s disease in adults NICE guideline, 2017.
  15. Bouça-Machado R, Titova N, Chaudhuri KR, Bloem BR, Ferreira JJ. Palliative care for patients and families with Parkinson’s disease. Int Rev Neurobiol Academic Press Inc. 2017; 132: 475-509.
  16. Ghoche R. The conceptual framework of palliative care applied to advanced Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: S2-5.
  17. Kluger BM. Palliative care for Parkinson’s disease and related disorders: stepping into the future. Ann Cardiothorac Surg 2020; 9: S3-S5.
  18. Garon M, Weck C, Rosqvist K, Odin P, Schrag A, Krikmann Ü i wsp. A systematic practice review: providing palliative care for people with Parkinson’s disease and their caregivers. Palliat Med 2024; 38: 57-68.
  19. Ng JSC. Palliative care for Parkinson’s disease. Ann Palliat Med 2018; 7: 296-303.
  20. Kluger BM, Fox S, Timmons S, Katz M, Galifianakis NB, Subramanian I i wsp. Palliative care and Parkinson’s disease: meeting summary and recommendations for clinical research. Parkinsonism Relat Disord 2017; 37: 19-26.
  21. Goy ER, Bohlig A, Carter J, Ganzini L. Identifying predictors of hospice eligibility in patients with Parkinson disease. Am J Hospice Palliat Med 2015; 32: 29-33.
  22. Nair K, Lee M, Hobson E, Oliver D, Husbands E. End-of-life care of people with long-term neurological conditions. Pract Neurol 2022; 22: 385-391.
  23. Thomas K, Watson M, Armstrong Wilson J. The gold standards framework: proactive identification guidance (PIG) (7th ed.). National GSF Centre 2022.
  24. Fabbri M, Kauppila LA, Ferreira JJ, Rascol O. Challenges and perspectives in the management of late-stage Parkinson’s disease. J Parkinsons Dis 2020; 10: S75-S83.
  25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-442.
  26. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C i wsp. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19: 1020-1028.
  27. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P i wsp. Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-2170.
  28. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP i wsp. The M<sup>o</sup>CA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717-1725.
  29. Dzierżanowski T, Gradalski T, Kozlowski M. Palliative performance scale: cross cultural adaptation and psychometric validation for Polish hospice setting. BMC Palliat Care 2020; 19: 52.
  30. Higginson IJ, Gao W, Saleem TZ, Chaudhuri KR, Burman R, McCrone P i wsp. Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One 2012; 7: 11.
  31. Waller A, Girgis A, Currow D, Lecathelinais C, Johnson C, Mitchell G i wsp. Development of the palliative care needs assessment tool (PC- NAT) for use by multi-disciplinary health professionals. Palliat Med 2008; 22: 956-964.
  32. Macchi ZA, Koljack CE, Miyasaki JM, Katz M, Galifianakis N, Prizer LP i wsp. Patient and caregiver characteristics associated with caregiver burden in Parkinson’s disease: a palliative care approach. Ann Cardiothorac Surg 2020: S24-S33.
  33. Gao W, Crosby V, Wilcock A, Burman R, Silber E, Hepgul N i wsp. Psychometric properties of a generic, patient-centred palliative care outcome measure of symptom burden for people with progressive long term neurological conditions. PLoS One 2016; 11: 10.
  34. Wilson R, Hepgul N, Saha RA, Higginson IJ, Gao W. Symptom dimensions in people affected by long-term neurological conditions: a factor analysis of a patient-centred palliative care outcome symptom scale. Sci Rep 2019; 9; 4972.
  35. Richfield EW, Johnson MJ. Palliative care in Parkinson’s disease: review of needs assessment tools. Ann Cardiothorac Surg 2020; 9: S6-S15.
  36. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s disease questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 1997; 26: 353-357.
  37. Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil 2009; 23: 362-370.
  38. Peterman AH, Fitchett G, Min D, Brady MJ, Hernandez L, Cella D. Measuring spiritual well- being in people with cancer: the functional assessment of chronic illness therapy-spiritual well-being scale (FACIT-Sp). Ann Behav Med 2002; 24: 49-58.
  39. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
  40. Gort AM, Mingot M, Gomez X, Soler T, Torres G, Sacristán O i wsp. Use of the Zarit scale for assessing caregiver burden and collapse in caregiving at home in dementias. Int J Geriatr Psychiatry 2007; 22: 957-962.
  41. Ramanathan U, Tanuseputro P. Improving access to palliative care for persons with Parkinson disease. Ann Cardiothorac Surg 2020; 9: 149-151.
  42. Bouça-Machado R, Lennaerts-Kats H, Bloem B, Ferreira JJ. Why palliative care applies to Parkinson’s disease. Mov Disord 2018; 33: 750-753.
  43. Bede P HOOD. An integrated framework of early intervention palliative care in motor neurone disease as a model to progressive neurodegenerative disease. Poster at European ALS Congress, Turin 2009.
  44. Rogers A, Richfield EW, Thomas S, Wee B, Trotter SA. Parkinson’s disease and palliative care: a quality of care Delphi study. BMJ Support Palliat Care 2023; 13: 255-262.
  45. Tarolli CG, Holloway RG. Palliative care and Parkinson’s disease: outpatient needs and models of care over the disease trajectory. Ann Cardiothorac Surg 2020; 9: S44-S51.
  46. Maisha T. Robinson M, Kevin M. Barrett M. Emerging subspecialties in neurology: neuropalliative care. Neurology 2014; 82: e180-182.
  47. Boersma I, Jones J, Coughlan C, Carter J, Bekelman D, Miyasaki J i wsp. Palliative care and Parkinson’s disease: caregiver perspectives. J Palliat Med 2017; 20: 930-938.
  48. Bruno V, Mancini D, Ghoche R, Arshinoff R, Miyasaki JM. High prevalence of physical and sexual aggression to caregivers in advanced Parkinson’s disease. Experience in the Palliative Care Program. Parkinsonism Relat Disord 2016; 24: 141-142.
  49. Fleisher JE, Hess SP, Klostermann EC, Lee J, Myrick E, Mitchem D i wsp. IN-HOME-PD: the effects of longitudinal telehealth-enhanced interdisciplinary home visits on care and quality of life for homebound individuals with Parkinson’s disease. Parkinsonism Relat Disord 2022; 102: 68-76.
  50. Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN i wsp. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology 2017; 89: 1152-1161.
  51. Kluger BM, Katz M, Galifianakis NB, Pantilat SZ, Hauser JM, Khan R i wsp. Patient and family outcomes of community neurologist palliative education and telehealth support in Parkinson disease. JAMA Neurol 2023; 81: 39-49.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
ZGŁASZANIE PRAC
Udostępnij
without publication fees
without publication fees
Dostępne w
Zintergrowane z
plagiat pl
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications